Skip to main content
AAN.com
Research Article
May 10, 2023

Conversion Rate of Essential Tremor to Essential Tremor Parkinson Disease
Data From a Prospective Longitudinal Study

Abstract

Background and Objectives

There has been a long-standing dialog as to whether essential tremor (ET) increases the risk of developing Parkinson disease (PD). While there are relevant cross-sectional data, there are almost no longitudinal prospective data. We quantified the conversion rate from ET to ETPD in a prospective longitudinal cohort study of patients with ET. We compared the observed rate with that reported in the epidemiologic literature.

Methods

We enrolled patients with ET in a prospective, longitudinal study. A senior movement disorders neurologist evaluated standardized neurologic examinations every 18 months.

Results

One hundred ninety-three patients with ET (mean age = 78.1 ± 9.6 years, range = 55–96) had a mean follow-up duration of 4.1 years. Seven (3.6%) converted from ET to ETPD. The incidence of PD among patients with ET was 7/792.9 person-years (py; i.e., 882.8/100,000 py). A meta-analysis of the incidence (per 100,000 py) of PD in 14 studies from 13 countries across 4 continents reported an incidence of PD = 61.21 (men, 40 years or older) and 37.55 (women, 40 years or older). The incidence/100,000 py in men peaked in the 80- to 89-year-old age group (258.47) and in women in the 80- to 89-year-old age group (103.48 py). The abovementioned published values are 3.4–23.5 times lower than the value we observed for ET.

Discussion

The incidence of PD in an ET cohort is substantially higher than that reported in historical population-based control groups across numerous countries. Additional prospective longitudinal data are needed to further explore this association.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Thenganatt MA, Jankovic J. The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2016;22(suppl 1):S162-S165.
2.
Tarakad A, Jankovic J. Essential tremor and Parkinson's disease: exploring the relationship. Tremor Other Hyperkinet Mov (N Y). 2019;8:589.
3.
LaRoia H, Louis ED. Association between essential tremor and other neurodegenerative diseases: what is the epidemiological evidence? Neuroepidemiology. 2011;37:1-10.
4.
Louis ED, Ottman R. Is there a one-way street from essential tremor to Parkinson's disease? Possible biological ramifications. Eur J Neurol. 2013;20(11):1440-1444.
5.
Adler CH, Shill HA, Beach TG. Essential tremor and Parkinson's disease: lack of a link. Mov Disord. 2011;26(3):372-377.
6.
Algarni M, Fasano A. The overlap between Essential tremor and Parkinson disease. Parkinsonism Relat Disord. 2018;46(suppl 1):S101-S104.
7.
Tan EK, Lee SS, Fook-Chong S, Lum SY. Evidence of increased odds of essential tremor in Parkinson's disease. Mov Disord. 2008;23(7):993-997.
8.
Benito-Leon J, Louis ED, Bermejo-Pareja F. Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2008;80(4):423-425.
9.
Rocca WA, Bower JH, Ahlskog JE, et al. Increased risk of essential tremor in first-degree relatives of patients with Parkinson's disease. Mov Disord. 2007;22(11):1607-1614.
10.
Costello S, Bordelon Y, Bronstein J, Ritz B. Familial associations of Alzheimer disease and essential tremor with Parkinson disease. Eur J Neurol. 2010;17(6):871-878.
11.
Spanaki C, Plaitakis A. Essential tremor in Parkinson's disease kindreds from a population of similar genetic background. Mov Disord. 2009;24(11):1662-1668.
12.
Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez JM, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004;62(5):734-741.
13.
Cersonsky TEK, Kellner S, Chapman S, Huey ED, Louis ED, Cosentino S. Profiles of normal cognition in essential tremor. J Int Neuropsychol Soc. 2020;26(2):197-209.
14.
Louis ED, Hernandez NC, Ottman R, Clark LN. Mixed motor disorder: essential tremor families with heterogeneous motor phenomenology. Neurol Clin Pract. 2021;11(6):e817-e825.
15.
Goetz CG, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-47.
16.
Louis ED, Ford B, Bismuth B. Reliability between two observers using a protocol for diagnosing essential tremor. Mov Disord. 1998;13(2):287-293.
17.
Louis ED, Hernandez N, Sebastian AA, Clark LN, Ottman R. Validity of probands' reports and self-reports of essential tremor: data from a large family study in North America. J Neurol Sci. 2018;393:45-50.
18.
Louis ED, Ottman R, Ford B, et al. The Washington Heights-Inwood genetic study of essential tremor: methodologic issues in essential-tremor research. Neuroepidemiology. 1997;16(3):124-133.
19.
Louis ED, Pullman SL. Comparison of clinical vs. electrophysiological methods of diagnosing of essential tremor. Mov Disord. 2001;16(4):668-673.
20.
Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42(6):1142-1146.
21.
Louis ED, Wise A, Alcalay RN, Rao AK, Factor-Litvak P. Essential tremor-Parkinson's disease: a double whammy. J Neurol Sci. 2016;366:47-51.
22.
Louis ED, Hernandez N, Michalec M. Prevalence and correlates of rest tremor in essential tremor: cross-sectional survey of 831 patients across four distinct cohorts. Eur J Neurol. 2015;22(6):927-932.
23.
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292-300.
24.
de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63(7):1240-1244.
25.
Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol. 2005;62(6):1004-1007.
26.
Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain. 2007;130(12):3297-3307.
27.
Shill HA, Adler CH, Beach TG. Lewy bodies in essential tremor are no different than in controls. Parkinsonism Relat Disord. 2016;23:106-107.
28.
Louis ED, Iglesias-Hernandez D, Hernandez NC, et al. Characterizing Lewy pathology in 231 essential tremor brains from the essential tremor centralized brain repository. J Neuropathol Exp Neurol. 2022;81(10):796-806.
29.
Louis ED, Barnes LF, Ford B, Ottman R. Family history information on essential tremor: potential biases related to the source of the cases. Mov Disord. 2001;16(2):320-324.
30.
Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012;78(18):1434-1440.
31.
Jensen-Roberts S, Myers TL, Auinger P, et al. A remote longitudinal observational study of individuals at genetic risk for Parkinson disease: baseline results. Neurol Genet. 2022;8(5):e200008.
32.
Dorsey ER, Darwin KC, Mohammed S, et al. Virtual research visits and direct-to-consumer genetic testing in Parkinson's disease. Digit Health. 2015;1:205520761559299.
33.
Myers TL, Tarolli CG, Adams JL, et al. Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants. Clin Park Relat Disord. 2021;4:100094.
34.
Chaudhuri KR, Buxton-Thomas M, Dhawan V, Peng R, Meilak C, Brooks DJ. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry. 2005;76(1):115-117.
35.
Konno T, Deutschlander A, Heckman MG, et al. Comparison of clinical features among Parkinson's disease subtypes: a large retrospective study in a single center. J Neurol Sci. 2018;386:39-45.
36.
van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ. Motor patterns in Parkinson's disease: a data-driven approach. Mov Disord. 2009;24(7):1042-1047.
37.
van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ. Patterns of motor and non-motor features in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009;80(8):846-850.

Information & Authors

Information

Published In

Neurology® Clinical Practice
Volume 13Number 3June 2023

Publication History

Received: November 21, 2022
Accepted: March 2, 2023
Published online: May 10, 2023
Published in print: June 2023

Permissions

Request permissions for this article.

Disclosure

The authors report no relevant disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

Study Funding

NINDS R01 NS086736.

Authors

Affiliations & Disclosures

Elan D. Louis, MD
Department of Neurology (EDL, DB, AG), University of Texas Southwestern Medical Center, Dallas, TX; and Taub Institute for Research on Alzheimer's Disease and the Aging Brain (SAC), G.H. Sergiesvky Center, and Department of Neurology, Columbia University Irving Medical Center, New York.
Disclosure
Scientific Advisory Boards:
1.
SAGE Pharmaceuticals
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
Dr. Louis is the Editor in Chief of Tremor and Other Hyperkinetic Movements. He receives no compensation.
Patents:
1.
NONE
Publishing Royalties:
1.
Merritt's Textbook of Neurology
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Dr. Louis has received research support from the National Institutes of Health: NINDS #R01 NS094607 (principal investigator), NINDS #R01 NS073872 (principal investigator), NINDS #R01 NS117745 (principal investigator) and NINDS #R01 NS088257 (principal investigator).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Expert testimony related to movement disorders, 2022
Diane Berry, PhD
Department of Neurology (EDL, DB, AG), University of Texas Southwestern Medical Center, Dallas, TX; and Taub Institute for Research on Alzheimer's Disease and the Aging Brain (SAC), G.H. Sergiesvky Center, and Department of Neurology, Columbia University Irving Medical Center, New York.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ali Ghanem, MD
Department of Neurology (EDL, DB, AG), University of Texas Southwestern Medical Center, Dallas, TX; and Taub Institute for Research on Alzheimer's Disease and the Aging Brain (SAC), G.H. Sergiesvky Center, and Department of Neurology, Columbia University Irving Medical Center, New York.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Stephanie A. Cosentino, PhD
Department of Neurology (EDL, DB, AG), University of Texas Southwestern Medical Center, Dallas, TX; and Taub Institute for Research on Alzheimer's Disease and the Aging Brain (SAC), G.H. Sergiesvky Center, and Department of Neurology, Columbia University Irving Medical Center, New York.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1. Travel funding from the University of Geneva to deliver Keynote Talk at Research Conference in December 20222. Travel funding from the University of Miami to attend a workshop on pre-symptomatic ADS in February 2023
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
I have served as a consultant for the Association for Frontotemporal Dementia and for Sage Therapeutics.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH NIA: K23 AG032899, PI, 2008-2013NIH NIA: R01 AG054525, PI, 2017 - 2022NIH NIA: U19 AG063893, Site MPI, 2019-2024NIH NINDS: R01 NS086736, Site PI, 2019-2024NIH NIA: R25AG059557, MPI, 2018-2023NIH NIA: P50AG008702, REC Module Leader, 2020 - 2025NIH NIMH: R01 MH120794 Co-I, 2019-2024NIH NIA: R01AG007370, Co-I, 2017-2022NIH NINDS: U24AG056270, Co-I, 2017-2022NIH NIA: R01AG058918, Co-I, 2018-2023NIH NIA: U19AG063911, Co-I, 2019-2024 NIH NIA: R01AG063888, Co-I, 2020-2025NIH NIA: U54NS092091, Co-I, 2019-2024
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Association for Frontotemporal Degeneration
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Louis [email protected]
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Submitted and externally peer reviewed. The handling editor was Associate Editor John P. Ney, MD, MPH.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Prodromal Parkinson’s Disease, Neurologic Clinics, (2025).https://doi.org/10.1016/j.ncl.2024.12.004
    Crossref
  2. Subjective Sleep Disturbance and Lewy Pathology: Data from a Cohort of Essential Tremor Brain Donors, Neurodegenerative Diseases, 24, 1, (6-15), (2024).https://doi.org/10.1159/000539032
    Crossref
  3. Essential tremor plus affects disease prognosis: A longitudinal study, Chinese Medical Journal, 138, 1, (117-119), (2024).https://doi.org/10.1097/CM9.0000000000003340
    Crossref
  4. Distinguishing essential tremor from Parkinson’s disease: clinical and experimental tools, Expert Review of Neurotherapeutics, 24, 8, (799-814), (2024).https://doi.org/10.1080/14737175.2024.2372339
    Crossref
  5. REM sleep behavior disorder and Prodromal Parkinson’s Disease in patients with Essential Tremor, Sleep Medicine: X, 8, (100118), (2024).https://doi.org/10.1016/j.sleepx.2024.100118
    Crossref
  6. Essential tremor as a prodromal feature of Parkinson's disease, Parkinsonism & Related Disorders, 128, (107128), (2024).https://doi.org/10.1016/j.parkreldis.2024.107128
    Crossref
  7. Update: Protective and risk factors for Parkinson disease, Parkinsonism & Related Disorders, 125, (107026), (2024).https://doi.org/10.1016/j.parkreldis.2024.107026
    Crossref
  8. Cranial Tremors in Essential Tremor: Prevalence, Anatomic Distribution and Predictors of Occurrence, Movement Disorders Clinical Practice, 12, 1, (57-65), (2024).https://doi.org/10.1002/mdc3.14271
    Crossref
  9. Prevalence of and Annual Conversion Rates to Mild Cognitive Impairment and Dementia: Prospective, Longitudinal Study of an Essential Tremor Cohort, Annals of Neurology, 95, 6, (1193-1204), (2024).https://doi.org/10.1002/ana.26927
    Crossref
  10. Study Answers Longstanding Question, Neurology Today, 23, 12, (29-31), (2023).https://doi.org/10.1097/01.NT.0000943120.40171.bf
    Crossref
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share